Jarod Facundo of The Capitol Forum stated in a post to X: “EXCLUSIVE – DOJ Antitrust leadership is considering changing the direction of its ongoing investigation into UnitedHealth (UNH) Group to focus on the company’s PBM, inspired by President Trump’s drug pricing executive order and comments criticizing health care ‘middlemen.'”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- UnitedHealth price target lowered to $385 from $400 at UBS
- UnitedHealth recommends shareholders reject mini-tender offer by Tutanota
- HHS, CMS announce pledge from insurers to improve MA authorization process
- Lawmakers aim at VA loophole letting insurers charge Medicare billions, WSJ says
- ‘Jump the Gun,’ Says Investor About UnitedHealth Stock